The Effect of Omalizumab on Airway Responsiveness to Adenosine in Patients With Poorly Controlled Asthma
Latest Information Update: 03 Nov 2021
At a glance
- Drugs Omalizumab (Primary)
- Indications Asthma
- Focus Pharmacodynamics
- Sponsors Novartis Pharmaceuticals Corporation
- 15 Feb 2009 Status changed from active, no longer recruiting to completed, as reported on ClinicalTrials.gov.
- 20 May 2007 Results have been reported.
- 24 Dec 2005 New trial record.